MAPT and Behcet disease: We also recently demonstrated that BD‐tau shows no or much weaker correlations with age, renal function, other comorbidities, and self‐identified race/ethnicity, compared with NfL [28], further supporting BD‐tau as a promising brain injury biomarker.